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Abstract
Background: Identifying genetic determinants for lung function is important in providing insight
into the pathophysiology of asthma. Signal transducer and activator of transcription 3 is a
transcription factor latent in the cytoplasm; the gene (STAT3) is activated by a wide range of
cytokines, and may play a role in lung development and asthma pathogenesis.
Methods: We genotyped six single nucleotide polymorphisms (SNPs) in the STAT3 gene in a
cohort of 401 Caucasian adult asthmatics. The associations between each SNP and forced
expiratory volume in 1 second (FEV1), as a percent of predicted, at the baseline exam were tested
using multiple linear regression models. Longitudinal analyses involving repeated measures of FEV1
were conducted with mixed linear models. Haplotype analyses were conducted using imputed
haplotypes. We completed a second association study by genotyping the same six polymorphisms
in a cohort of 652 Caucasian children with asthma.
Results: We found that three polymorphisms were significantly associated with baseline FEV1:
homozygotes for the minor alleles of each polymorphism had lower FEV1 than homozygotes for
the major alleles. Moreover, these associations persisted when we performed an analysis on
repeated measures of FEV1 over 8 weeks. A haplotypic analysis based on the six polymorphisms
indicated that two haplotypes were associated with baseline FEV1. Among the childhood
asthmatics, one polymorphism was associated with both baseline FEV1 and the repeated measures
of FEV1 over 4 years.
Conclusion: Our results indicate that genetic variants in STAT3, independent of asthma treatment,
are determinants of FEV1 in both adults and children with asthma, and suggest that STAT3 may
participate in inflammatory pathways that have an impact on level of lung function.
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Background
It is recognized that genetic factors influence lung func-
tion [1,2]. The identification of genetic variants that deter-
mine either lung function development or decline is
particularly important for diseases in which low lung
function is a feature, such as chronic obstructive pulmo-
nary disease and asthma, since this provides insight into
the pathophysiology of these disorders. This may also be
relevant to non-pulmonary disorders that have been asso-
ciated with low lung function, such as cardiovascular dis-
orders [3,4] and diabetes [5], in which these genes may
control systemic mechanisms (e.g. inflammation) that
contribute to both low lung function and disease
development.
Signal transducer and activator of transcription 3 (STAT3)
is a member of a protein family of transcription factors,
which was discovered in the course of studies of inter-
feron-induced intracellular signal transduction [6]. These
proteins are latent in the cytoplasm and become activated
through tyrosine phosphorylation which typically occurs
through cytokine receptor associated kinases (the Janus
kinase-signal transducer or JAKs). The JAK-STAT pathway
transmits information received from extracellular
polypeptide signals, through membrane receptors,
directly to target gene promoters in the nucleus, providing
a mechanism for transcriptional regulation without sec-
ond messengers. The gene, STAT3, is induced by a wide-
array of cytokines, including interleukin (IL)-6, IL-10, and
IL-13, and has been implicated in the regulation of cell
growth, inflammation, immune tolerance and early
embryonic development. Recently, STAT3 was implicated
in asthma pathogenesis in a study that showed that
STAT3-dependent pathways induced by IL-13 in lung
myofibroblasts were inhibited by the administration of
the inhaled corticosteroid, fluticasone [7]. This suggests a
role in airway inflammation and remodeling in asthmat-
ics, which may affect lung function level.
In a previous study of the pharmacogenetics of asthma
treatment, STAT3 was one of the candidate genes that we
screened for association with response to cortocosteroid
treatment [8]. Single nucleotide polymorphisms (SNPs)
in STAT3 were genotyped and tested in a screening dataset
from an adult asthma clinical trial. No effect of STAT3
SNPs on asthma drug response was seen in that study.
However, the polymorphisms affected baseline lung func-
tion. In this report, we present our analysis of the associa-
tion of STAT3 SNPs with lung function in adults with
asthma, and replicate our findings in a cohort of children
with asthma.
Methods
Populations and Study Samples
We used information from two asthma clinical trials, as
previously reported [8]. All patients or their legal guardi-
ans consented to the study protocol and ancillary genetic
testing. The Adult Study was a multicenter 8-week rand-
omized clinical trial comparing the effect of once-daily
high-dose inhaled flunisolide therapy with that of stand-
ard inhaled corticosteroid therapy (i.e. high vs standard
dose inhaled corticosteroid therapy) among moderate to
severe adult asthmatics [8]. Inclusion criteria were a his-
tory of asthma, ≥  12% improvement in FEV1  with
albuterol, and use of inhaled steroids at randomization.
Exclusion criteria were non-asthma pulmonary disease,
smoking (≥  10 pack-years), and recent asthma exacerba-
tions requiring systemic steroids. Subjects were phoned
weekly and had spirometry at 4 and 8 weeks. For this anal-
ysis, we included only the 401 Caucasian participants. The
Childhood Asthma Management Program (CAMP) is a
multicenter, randomized, double-blinded clinical trial
testing the safety and efficacy of inhaled budesonide vs.
nedocromil vs. placebo over a mean of 4.3 years. Trial
design and methodology for CAMP have been published
[9,10]. CAMP enrolled 1,041 children ages 5 to 12 years
with mild to moderate asthma. Entry criteria included
asthma symptoms and / or medication use for ≥  6-months
in the previous year and airway responsiveness with a pro-
vocative concentration of methacholine causing a 20%
reduction in FEV1 (PC20) ≤  12.5 mg/ml. Data for 652 Cau-
casian children were included in this analysis.
Phenotypes
The primary phenotype of interest in both cohorts was
baseline, pre-bronchodilator forced expiratory volume in
one second, as a percentage of predicted (PPFEV1). In the
Adult Study, baseline PPFEV1 was measured after an open-
label 4-week period that demonstrated stability on the
study drug or on standard inhaled therapy. Spirometry
was then performed at monthly intervals, for a total of
three spirometric measurements. In CAMP, baseline
spirometry was performed at randomization, after a 28-
day period during which only as-needed albuterol was
allowed. Follow-up spirometry was perfomed at 2, 4, 12,
16, 24, 28, 36, 40, and 48 months. In addition to the anal-
ysis of the baseline PPFEV1, a repeated measures analysis
was performed in both cohorts, making use of the longi-
tudinal follow-up for each subject. In CAMP, we included
information on parental smoking obtained from the base-
line questionnaire.
SNP Selection and Genotyping
SNPs were selected from two sources, public databases
and genomic DNA sequencing performed at the White-
head Institute. Three SNPs were discovered as a result of
the sequencing effort: G3363a3, G3363a4, andRespiratory Research 2005, 6:52 http://respiratory-research.com/content/6/1/52
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G3363a16. These three SNPs have been submitted to the
public database and correspond precisely to rs8075442,
rs2293152, and rs2306581, respectively (dbSNP: http://
www.ncbi.nlm.nih.gov/SNP). Five additional SNPs were
chosen from public databases for genotyping, with the
overall goal of having, on average, at least one SNP every
10 kilobases. Two of these SNPs – rs1803125 (exonic)
and rs744284 (promoter) – were found to be monomor-
phic in the Adult Study subjects, and were not subse-
quently genotyped in the CAMP cohort. Three additional
SNPs were successfully genotyped in both cohorts:
rs1026916, rs1905340, and rs957971. These are all
intronic SNPs (Figure 1[11,12]), and flanking sequences
are given in Table 1. Linkage disequilibrium (LD) between
each pair of SNPs was calculated and plotted using the
LDPlotter tool http://innateimmunity.net/IIPGA2/Bioin
formatics/, and expressed as the r2 LD statistic [13].
SNPs were genotyped via a SEQUENOM MassARRAY
MALDI-TOF mass spectrometer (Sequenom, San Diego,
CA) for analysis of unlabeled single-base extension min-
isequencing reactions with a semiautomated primer
design program (SpectroDESIGNER, Sequenom). Our
protocol implemented the very short extension method
[14], whereby sequencing products are extended by only
one base for three of the four nucleotides and by several
additional bases for the fourth nucleotide (representing
one of the alleles for a given SNP), permitting clearly
delineated mass separation of the two allelic variants at a
given locus.
Statistical Analysis
Single SNP association analyses were performed with SAS
statistical software (SAS Institute, Inc., Cary, NC). Univar-
iate associations between SNPs and the phenotype of
Table 1: Flanking sequences for STAT3 SNPs
STAT3 G3363a16 GGGAAAATGAGATCAGGAGATAAAG [G/T]GGCACCCTTTGGTCTTGTAAAGCCTTTTTTA
STAT3 G3363a3 ACAGACATCATTTGAACTAGAGACTCT [G/A]TCTTTATTCAGAGATCTTCATTTTGTGGAC
STAT3 G3363a4 TCCCCTTCACAAAGGGCCTCTGGCTGC [C/G]GGAGAGGGCTAGGGAGAGCCTCACAG
STAT3 rs1026916 AGGAAAAAGTTTAACCCAAAGACTGT [A/G]TGGATCTTCTCTACCCTACATCTCCAATCT
STAT3 rs1905340 TATTTGAGAATCTAAGAAAGTAGATCA [A/C]ACTAAATATTGATATGCAGACACTAAAATC
STAT3 rs957971 TGTTATATGAAGTGAATTAACCTCCTAT [C/G]GTACTTCAGTTTTCTCTATGCTAAAAGTGT
Positions of the STAT3 SNPs genotyped in both the Adult Study and the CAMP cohort Figure 1
Positions of the STAT3 SNPs genotyped in both the Adult Study and the CAMP cohort. From UCSC Genome 
Browser http://genome.ucsc.edu, May 2004 Human Reference Sequence Assembly[11,12]. UCSC webpage was accessed on 
March 18, 2005.
UCSC Genome Browser on Human May 2004 AssemblyRespiratory Research 2005, 6:52 http://respiratory-research.com/content/6/1/52
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interest (PPFEV1) were tested by univariate linear regres-
sion, as implemented in Proc Reg in SAS. Multivariable
linear regression models, were used to control for poten-
tial confounders. In these models, the genotype for each
SNP was coded as three-level categorical variables (addi-
tive genetic model) or as dummy-coded variables. Hardy-
Weinberg equilibrium for each SNP was tested using the
chi-square goodness-of-fit test as implemented in the
ALLELE Procedure in SAS.
The repeated measures analyses were carried out using a
mixed linear model as implemented in the MIXED Proce-
dure in SAS. A mixed linear model is a generalization of
the standard linear model where the data are permitted to
exhibit correlation and nonconstant variability, thereby
providing the flexibility of modeling the variances and
covariances of the data, in addition to the means. The cov-
ariance structure for the lung function data was specified
using an unstructured model, which provided the best fit
for the data after testing other covariance matrices (com-
pound symmetry, spatial exponential, autoregressive, and
autoregressive-heterogeneous). All models adjusted for
time (in weeks) and contained a SNP × time interaction
term. However, since the time interaction terms were not
significant in any of the models, they were dropped from
the final models presented in the results. Multiple testing
for the single SNP association analyses was addressed by
controlling the false discovery rate (FDR) using the
method of Benjamini and Liu[15,16] (FDR tool available
at https://innateimmunity.net/IIPGA2/Bioinformatics/.
Control of the FDR was set at the 0.05 threshold.
Haplotype associations were explored with score tests that
account for linkage phase ambiguity [17]. The score tests,
derived from generalized linear models, are used for glo-
bal tests of association, as well as haplotype-specific tests.
The haplo.stats program implements the methods of
Schaid et al, and was used for these analyses. Haplotypes
were imputed and frequencies estimated using the modi-
fied EM algorithm estimation facility in haplo.stats. Anal-
yses were run with and without adjustment for nongenetic
factors. We modified the method to include data from
individuals with partially missing marker information.
The minimum haplotype frequency was set at 2.5%. As
previously reported [8] in an analysis of 59 SNPs across
the genome, we found no evidence for population strati-
fication in either population.
Results
Baseline characteristics and genotype frequencies of the
six SNPs in both cohorts are shown in Table 2. G3363a3
in the Adult Study was the only SNP out of Hardy-Wein-
berg equilibrium, due to one rare individual who was
homozygous for the minor allele. Genotype frequencies
were also similar for both cohorts. Figure 2 plots the LD
patterns among the six SNPs, with the corresponding r2
values in Table 3. The LD patterns are similar in the two
cohorts.
Table 4 and Figure 3 show the results of linear regression
models for baseline PPFEV1. In the Adult Study, three
SNPs showed an effect on lung function. For G3363a16,
subjects who were homozygous TT had PPFEV1 levels that
were 6.85% lower than levels for GG homozygotes. Like-
wise, for rs1026916 and rs957971, subjects who were
homozygous for the minor allele had lower PPFEV1 values
than did subjects who were homozygous for the major
allele. These results remained significant after controlling
for the FDR (i.e. the p-values associated with each SNP
were smaller than the FDR threshold p-value, thus we
reject the null hypothesis of no significant association). In
the CAMP trial, only rs1026916 was significantly associ-
ated with baseline PPFEV1, however, this did not remain
statistically significant after controlling for the FDR (i.e.
the p-value was greater than the FDR threshold p-value,
thus we are unable to reject the null hypothesis of no sig-
nificant association). Although not statistically signifi-
cant, the direction of the changes in lung function
associated with variation in G3363a16 and rs957971 par-
alleled those of the Adult Study. Similar results were
obtained when we used raw pre-BD FEV1  measures,
adjusted for age, sex, and height. Additional control for
exposure to maternal smoking in utero or post-natal
maternal or paternal smoking did not change the results.
Interactions between individual SNPs and parental smok-
ing variables were not significant. There was no significant
association of any of the SNPs with forced vital capacity.
We then took the SNPs that were significant in the base-
line analysis and performed a repeated measures analysis
in each cohort, to take advantage of the multiple measures
of PPFEV1. In the Adult Study, all 401 participants had
complete data on PPFEV1 at all three time points. In the
repeated measures analysis, results were similar to those
of the analyses on baseline PPFEV1 (Table 5), although
only the results for G3363a16 and rs957971 remained
significant after control for FDR. Since there were no dif-
ferences in PPFEV1 levels at baseline or at any time point
between the two treatment groups, we did not addition-
ally control for treatment group in the multivariable lon-
gitudinal models. For CAMP, 6358 observations were
available for analysis: 557 (85.3%) children had complete
information for the 10 time points, 56 (8.6%) had
information for 9 time points, 18 (2.8%) had information
for 8 time points, and 22 (3.4%) had information for 3 to
7 time points. In CAMP, rs1026916 was associated with
lung function over the 4 years of observation, and strati-
fied analyses showed similar effects of the SNP across
treatment groups. Although treatment group had a
significant effect on PPFEV1 over time, a formal test forRespiratory Research 2005, 6:52 http://respiratory-research.com/content/6/1/52
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interaction between SNP and treatment group was not sig-
nificant. Thus, treatment group was left as a covariate in
the final models. In both cohorts, the SNP × time interac-
tion terms were not significant, meaning that the effects of
the individual SNPs did not vary over the time of each
study.
Table 2: Baseline characteristics and genotype frequencies for the 6 SNPs in both cohorts.
Adult Study N = 401 CAMP N = 652
Age, mean(sd) 39.2 (13.7) 8.9 (2.1)
Gender, male, n(%) 171 (42.8) 393 (60.3)
FEV1 (%predicted), mean (sd) 71.7 (12.8) 94.3 (14.2)
Number of positive skin tests, median (minimum, maximum) --- 4 (0, 18)
Eosinophil count, geometric mean (sd) --- 5.86 (2.06)
IgE, geometric mean (sd) --- 404.0 (4.9)
Paternal asthma, n(%) --- 125 (19.2)
Maternal asthma, n(%) --- 164 (25.2)
Maternal cigarette smoking during pregnancy, n(%) --- 88 (13.5)
SNP genotypes, n(%) HWE p-value HWE p-value
G3363a16 GG 145 (36.2) 245 (37.6)
GT 153 (38.0) 0.6 291 (44.6) 0.7
TT 46 (11.5) 80 (12.3)
missing 57 (14.2) 36 (5.5)
G3363a3 GG 342 (85.2) 582 (89.3)
GA 1 (0.2) 0.004 2 (0.3) 1.0
AA 1 (0.2) 0
missing 57 (14.2) 68 (10.4)
G3363a4 GG 137 (34.0) 218 (33.4)
GC 175 (43.8) 0.3 291 (44.6) 0.5
CC 70 (17.5) 85 (13.0)
missing 19 (4.8) 58 (8.9)
rs1026916 GG 164 (41.0) 227 (34.8)
GA 181 (45.0) 0.8 233 (35.7) 0.2
AA 52 (13.0) 74 (11.3)
missing 4 (1.0) 118 (18.1)
rs1905340 CC 203 (50.8) 254 (39.0)
CA 159 (39.5) 1.0 191 (29.3) 0.6
AA 30 (7.5) 41 (6.3)
missing 166 (25.5)
rs957971 CC 156 (39.0) 242 (37.1)
CG 172 (42.8) 0.6 260 (39.9) 1.0
GG 54 (13.5) 70 (10.7)
missing 80 (12.3)
Table 3: Linkage disequilibrium (r2) among the six STAT3 SNPs*.
Adult Study G3363a16 G3363a3 G3363a4 rs1026916 rs1905340 rs957971
CAMP
G3363a16 0.0089 0.1662 0.9804 0.6985 0.9936
G3363a3 0.0016 0.0003 0.0076 0.0018 0.0017
G3363a4 0.1668 0.0012 0.1418 0.1051 0.1666
rs1026916 0.9754 0.0037 0.1627 0.6693 0.9718
rs1905340 0.6563 0.0002 0.0888 0.6644 0.6910
rs957971 0.9734 0.0036 0.1615 0.9854 0.6536
*r2 between SNPs for the Adult Study are above the diagonal and for the CAMP Study are below the diagonalRespiratory Research 2005, 6:52 http://respiratory-research.com/content/6/1/52
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Haplotype analyses on baseline PPFEV1 were performed
for each cohort. Table 6 presents the results for the Adult
Study. There were five haplotypes that had frequencies
above 2.5%. The global statistic was significant at p =
0.02. Haplotype 5, which is comprised of the major alleles
for G3363a16, rs957971, and rs1026916, was positively
associated with PPFEV1, meaning that this haplotype was
associated with higher PPFEV1 values. On the other hand,
haplotype 1, which contained the minor alleles of these
three SNPs, was negatively associated with PPFEV1. These
results were consistent with those of the single SNP anal-
ysis. Haplotype analysis in CAMP was also consistent with
the single SNP analyses, but did not reach statistical signif-
icance (data not shown).
Discussion
This is the first report of an association between SNPs in
the STAT3 gene and lung function in human populations.
In this study, we show an association between SNPs in the
STAT3 gene and FEV1 among asthmatics. These results are
reasonably robust and are consistent in a cohort of adult
asthmatics and a cohort of childhood asthmatics.
Although only one SNP was significant in both cohorts,
the direction of the effect of each individual SNPs was
similar in the two cohorts. These effects were seen when
we analyzed baseline FEV1 and the repeated measures of
FEV1 over 8 weeks in the adult cohort and over 4 years in
the childhood asthma cohort. In the cohort of childhood
asthmatics, these effects were independent of parental
smoking and asthma treatment group.
STAT proteins comprise a family of transcription factors
latent in the cytoplasm, that are activated by a series of
extracellular signaling proteins such as cytokine, growth
factors, and hormones that bind to specific cell-surface
receptors. The resulting signal transduction pathways per-
mit them to play different roles in normal physiological
cell processes, such as differentiation, proliferation, apop-
tosis, and angiogenesis [18,19]. Whereas other members
of this gene family have generally demonstrated specifi-
city in individual signaling pathways, STAT3 is deployed
in various, sometimes disparate, physiological processes
[6], including cell growth and differentiation [20], apop-
tosis [21], and anti-inflammatory processes mediated by
IL-10 [22], to name a few. Additionally, while the differ-
ent functions of the members of this gene family have
been elucidated via targeted gene ablation, ablation of
STAT3  leads to embryonic lethality in transgenic mice
[23], underscoring its importance in embryogenesis.
Linkage disequilibrium (LD) plots among the six STAT3 SNPs for both cohorts Figure 2
Linkage disequilibrium (LD) plots among the six STAT3 SNPs for both cohorts.LD is expressed as the r2 statistic.Respiratory Research 2005, 6:52 http://respiratory-research.com/content/6/1/52
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In the lung, the function of STAT3 has not been fully elu-
cidated. However, STAT3 appears to play a role in the reg-
ulation of surfactant [24,25], and in the inflammatory
response in acute lung injury [26,27]. Additionally, STAT3
is an important mediator in the pro-inflammatory effects
of the Th2 cytokine IL-13 on lung myofibroblasts [7,28].
It is plausible that our results are due to an effect of the
STAT3 gene during the embryonic stage of lung develop-
ment. However, the results in the CAMP cohort show that
this effect, if present, is likely a small one. On the other
hand, STAT3 had stronger effects on lung function in the
adult asthmatics, and a potential explanation for our find-
ings is that STAT3 interacts with pro-inflammatory envi-
ronmental stimuli, such as tobacco smoke, to affect FEV1
level. It is known that at least three factors determine lung
function at a particular point in adult life: (1) the maxi-
mally attained level of lung function; (2) the onset of
decline of lung function (or alternatively, the duration of
the plateau phase); and (3) the rate of decline of lung
function [29]. Whether STAT3  affects only a particular
phase of lung growth or decline, or affects all phases
remains to be seen. Furthermore, it needs to be deter-
mined whether this effect of STAT3  on FEV1  level is
unique to asthmatics or also applies to non-asthmatics.
Because the effects of STAT3 were stronger in the Adult
Study, we additionally hypothesized that STAT3  may
interact with environmental exposures to cause a decre-
ment in lung function. Since cigarette smoking is estab-
lished as the major environmental risk factor for low lung
function[30], we hypothesized that exposure to cigarette
smoke (either personal smoking or environmental
tobacco smoke) could potentially interact with STAT3. We
were unable to test the interaction between STAT3 and
smoking in the Adult Study, because participants were
non-smokers. In CAMP, we did not see a significant inter-
action effect between the individual SNPs and parental
smoking variables (in utero smoke exposure, maternal
smoking, paternal smoking), and too few children
smoked to permit any meaningful interaction analyses. It
is also possible that other environmental exposures that
we did not measure could be interacting with STAT3.
A limitation of our study is the lack of complete sequence
information on the gene. The sequencing efforts focused
Table 4: Results of linear regression models for baseline PPFEV1*
Adult Study CAMP
Stat3 SNPs β  (se)† Additive genetic 
model p-value‡
FDR threshold 
(decision§)
β  (se)† Additive genetic 
model p-value‡
FDR threshold 
(decision§)
G3363a16
Intercept (GG) 74.03 (1.06) 95.67 (0.92)
GT -3.35 (1.48) 0.0007 0.007 -1.93 (1.25) 0.1 0.02
TT -6.85 (2.15) (reject) -2.08 (1.84) (accept)
G3363a4
Intercept (GG) 70.76 (1.10) 94.19 (0.98)
GC 1.18 (1.47) 0.3 0.05 1.06 (1.29) 0.6 0.03
CC 2.04 (1.89) (accept) -2.04 (1.86) (accept)
rs1026916
Intercept (GG) 73.59 (0.93) 96.21 (0.95)
GA -2.90 (1.38) 0.004 0.01 -2.21 (1.33) 0.02 0.007
AA -5.22 (2.03) (reject) -4.11 (1.90) (accept)
rs1905340
Intercept (CC) 73.04 (0.89) 95.52 (0.89)
CA -3.00 (1.34) 0.04 0.03 -1.18 (1.36) 0.8 0.05
AA -2.77 (2.49) (accept) 0.70 (2.39) (accept)
rs957971
Intercept (CC) 73.48 (1.02) 95.56 (0.01)
CG -2.10 (1.41) 0.007 0.02 -2.07 (1.26) 0.08 0.01
GG -5.34 (2.00) (reject) -2.64 (1.91) (accept)
* Results are from individual linear regression models.
† β  's and p-values are from linear regression models with dummy-coded genotype categories.
‡ p-values refer to the categorical genotype variable (0, 1, 2), for the number of minor alleles present.
§Refers to the decision of whether to accept or reject the null hypothesis of no genotype effect. Please see text for further details.Respiratory Research 2005, 6:52 http://respiratory-research.com/content/6/1/52
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The association between STAT3 SNPs and FEV1 Figure 3
The association between STAT3 SNPs and FEV1. Mean (± sd) percent predicted FEV1 in the Adult Study plotted against 
genotype for each SNP. Additive genetic models were statistically significant for each SNP: p = 0.0007, 0.0043, and 0.007, 
respectively for G3363a16, rs1026916, and rs957971.
Table 5: Effects of Stat3 SNPs on repeated measures of PPFEV1 over time*
Adult Study CAMP
Stat3 SNPs β  (se) Additive genetic 
model p-value‡
FDR threshold 
(decision§)
β  (se) Additive genetic 
model p-value‡
G3363a16
Intercept (GG) 73.85 (1.21)
GT -2.72 (1.69) 0.008 0.009 --- ---
TT -6.33 (2.46) (reject)
rs1026916
Intercept (GG) 73.46 (1.13) 97.01 (0.93)
GA -2.25 (1.56) 0.028 0.017 -0.19 (0.99) 0.02
AA -4.74 (2.30) (accept) -4.24 (1.49)
rs957971
Intercept (CC) 73.36 (1.16)
CG -1.51 (1.60) 0.036 0.038 --- ---
GG -5.04 (2.29) (reject)
* β 's obtained from mixed models of repeated measurements of percent predicted FEV1 over time. All models are adjusted for time in weeks, with 
a maximum of 3 observations for the Adult Study, and 10 observations for the CAMP study. The model for CAMP is adjusted additionally for 
treatment group.
§Refers to the decision of whether to accept or reject the null hypothesis of no genotype effect. Please see text for further details.
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only on the exons, thus limiting our knowledge of the full
linkage disequilibrium pattern of the gene. Furthermore,
since all the SNPs we successfully genotyped were in
intronic regions of the gene, it is likely that these are not
responsible for the association but are rather in linkage
disequilibrium with the functional variant of this gene, or
with variants in another gene. Studying other popula-
tions, such as general population samples or occupational
cohorts with exposure information, may help elucidate
the effects of this gene on FEV1. Additionally, more func-
tional studies of SNPs in STAT3 are needed to elucidate its
role in lung function development.
Airway hyperresponsiveness was not assessed in the Adult
Study. However, the subjects had a physician diagnosis of
moderate to severe asthma (as evidenced by the levels of
lung function), were on inhaled steroids at baseline, and
had a significant bronchodilator response to albuterol.
The combination of a physician diagnosis and
bronchodilator response is a reasonable definition of
asthma in genetic studies[31]. Furthermore, significant
smoking and non-asthma respiratory disorders were
excluded. Additionally, we did not have information on
allergy outcomes in the Adult Study, either. In CAMP, we
performed additional analyses, however, there were no
associations between any of the STAT3  SNPs or either
serum IgE level or skin test reactivity.
We controlled for multiple testing by controlling the false
discovery rate. An additional strategy we took to minimize
the effect of multiple testing is by performing a screening
analysis in the Adult Study, then performing a replicate
analysis in CAMP. Population stratification is another
potential concern [32]; thus, we included only Caucasian
subjects in this analysis. Furthermore, in previous testing
utilizing a panel of 59 random markers, we found no evi-
dence for stratification in the Caucasian subjects in either
of these two cohorts [8].
Conclusion
We have shown that polymorphisms in STAT3 are associ-
ated with FEV1 in asthmatics. We show these effects both
in a cohort of adult asthmatics and in a cohort of child-
hood asthmatics. In both cohorts, we excluded gross
population stratification by testing with a panel of ran-
dom markers. The precise mechanism for the effects of
this gene on FEV1 remains unknown. However, while we
see an association between SNPs in this gene and FEV1 in
young asthmatics, the effects were stronger in the adult
asthmatics, suggesting a role of STAT3 in chronic inflam-
matory pathways that may have an impact on lung growth
and decline.
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